8-K: Cencora Reports Strong Q3 Results, Raises Full-Year Guidance

Cencora's third-quarter revenue increased by 10.9% year-over-year to $74.2 billion, leading to an increase in adjusted diluted EPS and an updated full-year outlook.

Summary

• Cencora reported a 10.9% increase in revenue to $74.2 billion for the third quarter of fiscal year 2024.
• GAAP diluted earnings per share (EPS) was $2.42, up from $2.35 in the prior year.
• Adjusted diluted EPS increased by 14.4% to $3.34, compared to $2.92 in the same quarter last year.
• The company has raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.55 to $13.65, up from the previous range of $13.35 to $13.55.
• U.S. Healthcare Solutions revenue increased by 12.2%, while International Healthcare Solutions revenue was flat year-over-year.
• The company's gross profit was $2.4 billion, a 6.5% increase compared to the same period in the previous fiscal year.
• Operating expenses increased by 9.0% to $1.7 billion, primarily due to litigation and opioid-related expenses.
• Net interest expense decreased by 45.9% to $31.3 million due to higher investment interest rates and lower variable-rate borrowings.
• The company expects full-year revenue growth of approximately 12%, with U.S. Healthcare Solutions growing between 12% and 13% and International Healthcare Solutions growing between 4% and 6%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased adjusted EPS, and raised full-year guidance. While there are some challenges, the overall tone is optimistic and confident.

Positives

• Cencora experienced strong revenue growth of 10.9% in the third quarter, reaching $74.2 billion.
• Adjusted diluted EPS increased by 14.4%, demonstrating improved profitability.
• The company raised its full-year adjusted diluted EPS guidance, indicating confidence in future performance.
• U.S. Healthcare Solutions segment showed robust growth with a 12.2% increase in revenue.
• Net interest expense decreased significantly by 45.9%, positively impacting the bottom line.
• The company declared a quarterly cash dividend of $0.51 per share, rewarding shareholders.
• Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500.

Negatives

• Operating expenses increased by 9.0% to $1.7 billion, primarily due to litigation and opioid-related expenses.
• Gross profit margin decreased by 13 basis points due to lower margins on GLP-1 class products.
• International Healthcare Solutions segment operating income decreased by 4.1%, partially offsetting gains in the U.S. segment.
• Operating income as a percentage of revenue decreased by 9 basis points.

Risks

• The company faces litigation and opioid-related expenses, which increased operating expenses.
• The gross profit margin declined due to increased sales of lower-margin products in the GLP-1 class.
• The International Healthcare Solutions segment experienced a decrease in operating income, indicating potential challenges in that market.
• The company's forward-looking statements are subject to uncertainty and changes in circumstances.

Future Outlook

Cencora has raised its full-year adjusted diluted EPS guidance to a range of $13.55 to $13.65 and expects revenue growth of approximately 12%.

Management Comments

• We are pleased to raise our fiscal 2024 guidance following Cencora's strong third quarter results, as our purpose-driven team members exhibited another quarter of solid execution against our pharmaceutical-centric strategy, said Steven H. Collis, Chairman, President & Chief Executive Officer of Cencora.
• Throughout my time as Cencora's CEO, our strategic positioning at the center of healthcare has allowed our company to capitalize on market growth and innovation while enhancing our capabilities to help our customers navigate the complexity of the ever-changing healthcare environment, Mr. Collis continued.
• As I move into my new role as Executive Chairman of the Board on October 1st, I am incredibly proud of the growth and evolution of our enterprise, and as COO Bob Mauch concurrently transitions into his new role of CEO, I am confident that Cencora will continue to drive long-term value creation for its partners and stakeholders.

Industry Context

Cencora's results reflect the ongoing growth in the pharmaceutical and healthcare sectors, particularly in the U.S. market, with increased demand for specialty products and GLP-1 class medications. The company's focus on pharmaceutical solutions and its strategic positioning within the healthcare ecosystem appear to be driving its performance.

Comparison to Industry Standards

• Cencora's 10.9% revenue growth is strong compared to some of its peers in the pharmaceutical distribution industry, such as Cardinal Health and McKesson, which have seen more modest growth in recent quarters.
• The adjusted diluted EPS growth of 14.4% is also a positive indicator, suggesting that Cencora is managing its costs effectively while growing its top line.
• The company's focus on specialty products and its strong performance in the U.S. Healthcare Solutions segment align with industry trends towards higher-margin pharmaceutical products.
• The decrease in gross profit margin due to GLP-1 products is a common trend in the industry, as these products often have lower margins due to pricing pressures and volume discounts.
• Cencora's ranking as #1 in Customer Satisfaction with Chain Drug Store Pharmacies by J.D. Power for Good Neighbor Pharmacy is a significant achievement, setting it apart from competitors in the retail pharmacy space.

Management Changes

Legal Proceedings

• The company incurred litigation and opioid-related expenses in the current quarter.

Stakeholder Impact

• Shareholders will benefit from the increased adjusted EPS and raised guidance, as well as the declared dividend.
• Employees are recognized for their contributions to the company's strong performance.
• Customers will continue to receive reliable delivery of pharmaceuticals and healthcare products.
• The company's strong financial position benefits suppliers and creditors.

Next Steps

• Cencora will host a conference call to discuss its operating results on July 31, 2024.
• Cencora management will attend several investor conferences in September 2024.
• The company will continue to focus on its pharmaceutical-centric strategy and drive long-term value creation.

Key Dates

Keywords

Cencora, pharmaceutical, healthcare, revenue, earnings, EPS, guidance, financial results, pharmacy, Good Neighbor Pharmacy